Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: MK-2206|DRUG: Exemestane|DRUG: Goserelin
Sponsor: Vanderbilt-Ingram Cancer Center